Editas Medicine (EDIT) Operating Margin (2015 - 2025)
Editas Medicine (EDIT) reported Operating Margin of 325.44% for Q3 2025, up 10732374.0% year-over-year from N/an in Q3 2024, and up 77.41% quarter-over-quarter from 1440.58% in Q2 2025.
Editas Medicine (EDIT) Operating Margin (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 11 years of Operating Margin data on file, last reported at 325.44% in Q3 2025.
- Operating Margin for Q3 2025 came in at 325.44%, up 10732374.0% year-over-year; the trailing twelve-month figure through Sep 2025 was 428.71% (down 5868.0% YoY), and the FY2024 annual result was 777.22%, down 56067.0% from the prior year.
- Operating Margin grew to 325.44% in Q3 2025 per EDIT's latest filing, from 1440.58% in the prior quarter.
- Over five years, Operating Margin peaked at 39.9% in Q4 2023 and troughed at 136952.38% in Q3 2022.
- A 5-year average of 15270.04% and a median of 940.09% in 2023 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2022 and 2023: Operating Margin slumped 13631896 bps in 2022, then surged 13601229 bps in 2023.
- A 5-year view of Operating Margin shows it stood at 333.71% in 2021, then plunged by 191 bps to 970.72% in 2022, then surged by 96 bps to 39.9% in 2023, then sank by 282 bps to 152.24% in 2024, then plunged by 114 bps to 325.44% in 2025.
- Business Quant data shows EDIT's Operating Margin at 325.44% in Q3 2025, 1440.58% in Q2 2025, and 1635.1% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Editas Medicine | 262.77 Mn | 262.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -325.44% |
| Jun 30, 2025 | -1,440.58% |
| Mar 31, 2025 | -1,635.10% |
| Dec 31, 2024 | -152.24% |
| Sep 30, 2024 | -107,649.18% |
| Jun 30, 2024 | -14,016.18% |
| Mar 31, 2024 | -5,902.29% |
| Dec 31, 2023 | -39.90% |
| Sep 30, 2023 | -940.09% |
| Jun 30, 2023 | -1,527.33% |
| Mar 31, 2023 | -517.32% |
| Dec 31, 2022 | -970.72% |
| Sep 30, 2022 | -136,952.38% |
| Jun 30, 2022 | -852.47% |
| Mar 31, 2022 | -749.52% |
| Dec 31, 2021 | -333.71% |
| Sep 30, 2021 | -633.42% |
| Jun 30, 2021 | -14,617.68% |
| Mar 31, 2021 | -875.26% |
| Dec 31, 2020 | -576.86% |